Put companies on watchlist
MEDIQON Group AG
ISIN: DE0006618309
WKN: 661830
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

MEDIQON Group AG · ISIN: DE0006618309 · EQS - adhoc news (50 News)
Country: Germany · Primary market: Germany · EQS NID: 1303259
15 March 2022 05:50PM

MEDIQON Group AG: Capital Increase via subscription rights issue resolved


DGAP-Ad-hoc: MEDIQON Group AG / Key word(s): Corporate Action
MEDIQON Group AG: Capital Increase via subscription rights issue resolved

15-March-2022 / 17:50 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


MEDIQON Group AG: Capital Increase via subscription rights issue resolved

The Management Board of MEDIQON Group AG (ISIN: DE0006618309) today resolved, with the approval of the supervisory board, to increase the share capital of the company from 10,999,513.00 to EUR 14,999,333.00 by issuing up to 3,999,820 new shares against cash distribution with subscription rights of the shareholders of the Company and by partially utilizing the authorized capital of the company.

The securities prospectus and the subscription offer are expected to be published - subject to the approval of the prospectus by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, "BaFin") - in calendar week 11 (March 21 - 25, 2022).

The subscription price amounts to EUR 10.40 per share. The price has been set based on the valuation logic used for the capital increase in November 2021.

The statutory subscription rights will be granted by way of by way of indirect subscription rights. The subscription ratio has been set at 11:4, i.e. eleven existing shares entitle to subscribe for four new shares at the subscription price. The subscription period is expected to start on the first banking day after the prospectus was published at 0:00 and run for 10 banking days (inclusive). Existing shares of MEDIQON Group AG are expected to be listed "Ex-Subscription Right" on the first day of the subscription period, expected to be March 23, 2022.

Shares for which subscription rights have not been exercised during the subscription period will be offered to selected qualified investors in a private placement.


15-March-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: MEDIQON Group AG
Herzog-Adolph-Strasse 2
61462 Königstein im Taunus
Germany
Phone: +49 (0) 6174-9687040
Fax: +49 (0) 6174-9687043
E-mail: ir@mediqon-group.de
Internet: www.mediqon-group.de
ISIN: DE0006618309, DE000A254TL0
WKN: 661830, A254TL
Listed: Regulated Unofficial Market in Berlin, Frankfurt (Basic Board), Stuttgart
EQS News ID: 1303259

 
End of Announcement DGAP News Service

1303259  15-March-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1303259&application_name=news&site_id=boersengefluester_html
Visual performance / price development - MEDIQON Group AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.